# Dr Aayush Gupta: curriculum vitae

> Dr Aayush Gupta, Professor and Head, Department of Dermatology, Venereology and Leprology, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Pimpri, Pune. Source: https://aayushgupta.co/cv (updated 2026-10-15).

Aayush Gupta is Professor and Head of the Department of Dermatology, Venereology and Leprology at Dr. D.Y. Patil Medical College, Hospital and Research Centre, Dr. D.Y. Patil Vidyapeeth, Pimpri, Pune. He is Director of Strategic Initiatives at the medical college, heads the Bioprinting Laboratory of Dr. D.Y. Patil Vidyapeeth and directs the MD dermatology residency programme. He founded Qtanea Solutions Private Limited, which makes Vybe, a vibratory anaesthesia device, and OpenScholar, a research information platform for universities, and he holds five patents in India and the United States. He has published 102 papers, is principal investigator on seven industry clinical trials and has raised nearly ₹7.5 crore for research, made up of nine extramural research grants and a ₹50 lakh seed fund for his company Qtanea Solutions. His research covers vitiligo, ichthyosis and other genodermatoses, leprosy, wound healing and imaging with artificial intelligence.

## Appointments
### At Dr. D.Y. Patil
- Professor and Head, Department of Dermatology, Venereology and Leprology
- Director of Strategic Initiatives, Dr. D.Y. Patil Medical College, Hospital and Research Centre
- Head, Bioprinting Laboratory, Dr. D.Y. Patil Vidyapeeth
- Programme Director, MD Dermatology residency

### Industry and editorial
- Founder and CEO, Qtanea Solutions Private Limited
- Clinical Advisory Board, Adiuvo Diagnostics
- Scientific Advisor, Clarivo Biosciences
- Consulting Editor, Clinical, Cosmetic and Investigational Dermatology

## Awards
- Dr A.S. Thambaiah Award, National Academy of Medical Sciences (NAMSCON 2022, Jaipur)
- Amritsar Award, National Academy of Medical Sciences (2022–23)
- Dhanvantri Award, Lokmat (2023)
- Two category awards, Indian Journal of Dermatology, Venereology and Leprology (Journal awards)
- Sakura Science Fellow, Japan Science and Technology Agency (Fellowship in Japan)

## Memberships
- Indian Association of Dermatologists, Venereologists and Leprologists (life member)
- International Society of Dermatology
- GUaRDIAN (rare-disease genomics consortium)

## Research programmes
- [Imaging and diagnostics](https://aayushgupta.co/research/imaging-and-diagnostics): 4 papers. A point-of-care multispectral imaging device with artificial intelligence was tested against standard care for leg ulcers in leprosy in a within-person randomised pilot trial. A real-time fluorescence imaging device guided antibiotic treatment in superficial skin infections, and a handheld screening device detects skin and soft tissue infections. He holds a United States patent and two Indian patents, assigned to Adiuvo Diagnostics, on devices and systems that detect pathogens and other cells.
- [Ichthyosis and genodermatoses](https://aayushgupta.co/research/ichthyosis-and-genodermatoses): 16 papers. Severe autosomal recessive congenital ichthyosis carries a heavy psychosocial burden for patients and families, and secukinumab reduced its inflammation but improved scaling only mildly. His group contributed to IndiGenomes, a resource of genetic variants from over 1,000 Indian genomes, and uses whole exome sequencing to diagnose rare genodermatoses. An ICMR grant funded a topical transglutaminase-1 nanocomplex for enzyme replacement, and a DBT grant starting in December 2026 will test non-viral delivery in a TGM1-deficient 3D human skin model.
- [Vitiligo and pigment biology](https://aayushgupta.co/research/vitiligo-and-pigment-biology): 15 papers. Vitiligo skin carries a lower ultraviolet signature than non-melanoma skin cancers, and its epidermis shows a strong anti-skin cancer signature in miRNA networks. The long noncoding RNA MALAT1 and the microRNA miR-31-5p both protect melanin-deficient vitiligo keratinocytes against ultraviolet damage to DNA. An ANRF grant now funds an immune-competent 3D human skin model of vitiligo.
- [Procedures and pain](https://aayushgupta.co/research/procedures-and-pain): 8 papers. In a split-lesion study, vibration-assisted anaesthesia reduced pain during dermatologic procedures, and Qtanea Solutions now makes the vibration device, Vybe. Fractional CO2 laser delivery of topical corticosteroids hastened resolution of plaque sarcoidosis, and a laser technique has been applied to the upper airway to treat habitual snoring. Other papers compare platelet-rich plasma with microneedling for androgenetic alopecia.
- [Leprosy and infection](https://aayushgupta.co/research/leprosy-and-infection): 15 papers. He is the principal investigator at Dr. D.Y. Patil on LIGHT, a Phase 3 Johnson & Johnson trial of bedaquiline in multibacillary leprosy, and on a Phase 0 study of plasma PGL-I for treatment monitoring. His clinical papers cover leprosy, the differential diagnosis of leonine facies, scrofuloderma and nodular secondary syphilis with granulomatous inflammation.
- [Wound healing and tissue engineering](https://aayushgupta.co/research/wound-healing-and-tissue-engineering): 2 papers. The Bioprinting Laboratory develops injectable granular hydrogels that combine extracellular-matrix mimicry with microporosity for skin tissue engineering. A DBT grant funds an automated spray device for autologous cell-grafted bioscaffolds. In vitiligo skin, miR-21-5p delays wound healing by regulating PDCD4 and Maspin.
- [Quality of life](https://aayushgupta.co/research/quality-of-life): 11 papers. In leprosy, internalised stigma rather than disability drives the loss of quality of life. His group has related quality of life to clinical severity in vitiligo, acne, melasma and keloids, and measured the psychosocial impact of severe congenital ichthyosis.

## Clinical trials (principal investigator on all 7)
- [Severe alopecia areata in adolescents: Deuruxolitinib](https://aayushgupta.co/trials/deuruxolitinib-alopecia-areata-adolescents). Placebo-controlled, Sun Pharma. Submitted to DCGI.
- [Multibacillary leprosy, treatment monitoring: Skin assessment chart and plasma PGL-I](https://aayushgupta.co/trials/pgl-i-leprosy-treatment-monitoring). Phase 0, Johnson & Johnson. Opens October 2026.
- [Non-segmental vitiligo: Topical AB1001](https://aayushgupta.co/trials/ab1001-non-segmental-vitiligo). Phase 2, Ahammune Biosciences. Opens October 2026.
- [Hair health in adults: H-Vit hair serum](https://aayushgupta.co/trials/h-vit-hair-serum). Observational, Systopic Laboratories. Opens October 2026.
- [Psoriasis: Guselkumab, subcutaneous](https://aayushgupta.co/trials/guselkumab-psoriasis-phase-4). Phase 4, Johnson & Johnson. Opens November 2026.
- [Multibacillary leprosy: Bedaquiline with rifampicin and clofazimine (LIGHT)](https://aayushgupta.co/trials/light-bedaquiline-multibacillary-leprosy). Phase 3, Johnson & Johnson. Under way since January 2025.
- [Atopic dermatitis, alopecia areata and vitiligo: Immuno-dermatology disease registry](https://aayushgupta.co/trials/immuno-dermatology-disease-registry). Registry, Pfizer. Started March 2025, completed.

## Research grants
- [Skin cell homeostasis](https://aayushgupta.co/grants/skin-cell-homeostasis). CSIR-IGIB, ₹4.5 lakh. Principal investigator · 2015 to 2017, completed.
- [Portable fluorescence dermascope to identify the pathogens of skin infection](https://aayushgupta.co/grants/fluorescence-dermascope-skin-infection). Adiuvo Diagnostics, ₹3.5 lakh. Principal investigator · 2019, completed.
- [Topical transglutaminase-1 nanocomplex for enzyme replacement in autosomal recessive congenital ichthyosis](https://aayushgupta.co/grants/tgm1-nanocomplex-congenital-ichthyosis). ICMR, ₹67.8 lakh. Principal investigator, with CSIR-IGIB · 2019 to 2021, completed.
- [Melanocyte and fibroblast cross-talk in keloids](https://aayushgupta.co/grants/keloid-melanocyte-fibroblast-crosstalk). IADVL, ₹5 lakh. Principal investigator · Since 2021, ongoing.
- [Fully automated device that sprays a sterile bioscaffold carrying the patient’s own cells](https://aayushgupta.co/grants/automated-autologous-cell-bioscaffold-spray). DBT, ₹85.5 lakh. Principal investigator, with CSIR-IGIB and BITS Pilani · Since 2023, ongoing.
- [Switchable bispecific BCMA/CD19 CAR-T cell therapy for refractory systemic lupus erythematosus](https://aayushgupta.co/grants/bispecific-car-t-lupus). ANRF, ₹3 crore. Principal investigator, with IIT Kanpur · Since December 2025, ongoing.
- [Immune-competent 3D human skin model of vitiligo](https://aayushgupta.co/grants/immune-competent-3d-skin-model-vitiligo). ANRF, ₹77 lakh. Joint principal investigator with Dr Rohit Kothari, with CSIR-IGIB · Since December 2025, ongoing.
- [Skin-on-Chip for screening cosmetic endocrine disruptors relevant to PCOS](https://aayushgupta.co/grants/skin-on-chip-endocrine-disruptors-pcos). ICMR, ₹85 lakh. Joint principal investigator with Dr Roopesh Rai · Since September 2026, ongoing.
- [Non-viral TGM1 delivery validated in a TGM1-deficient 3D human skin model](https://aayushgupta.co/grants/non-viral-tgm1-delivery-3d-skin-model). DBT, ₹70.82 lakh. Principal investigator, with CSIR-IGIB · Starts December 2026.
- Seed fund for Qtanea Solutions, ₹50 lakh.

## Patents
- [US 11,523,738](https://aayushgupta.co/patents/us-11-523-738): Pathogen detection device, United States, granted 13 December 2022
- [IN 323440](https://aayushgupta.co/patents/in-323440): Fluorescence detection of pathogens, India, granted 22 October 2019
- [IN 564943](https://aayushgupta.co/patents/in-564943): Detection of cellular entities, India, granted 4 April 2025
- [IN 559407](https://aayushgupta.co/patents/in-559407): Punch biopsy instrument, India, granted 31 January 2025
- [IN 499691](https://aayushgupta.co/patents/in-499691): Pain-abating device, India, granted 16 January 2024

## Recent papers (all 102: https://aayushgupta.co/publications)
- When biologics fail: Tofacitinib-induced remission in a child with severe, genetically ambiguous psoriasis. *Indian Journal of Dermatology, Venereology and Leprology*, 2026. Senior author. [doi:10.25259/ijdvl_1055_2025](https://doi.org/10.25259/ijdvl_1055_2025)
- Port-wine capillary malformation. *Journal of the American Academy of Dermatology*, 2026. [doi:10.1016/j.jaad.2026.09.005](https://doi.org/10.1016/j.jaad.2026.09.005)
- Measuring the composition and availability of human resources for health by sex in 204 countries and territories, 1990–2023, and workforce gaps for universal health coverage: a systematic analysis for the Global Burden of Disease Study 2023. *The Lancet Public Health*, 2026. [doi:10.1016/s2468-2667(26)00145-3](https://doi.org/10.1016/s2468-2667(26)00145-3)
- Comment on Case Series of Kaposi’s Varicelliform Eruption Associated with Underlying Primary Dermatoses. *Indian Journal of Dermatology*, 2026. Senior author. [doi:10.4103/ijd.ijd_858_25](https://doi.org/10.4103/ijd.ijd_858_25)
- Nevus of Ota. *Journal of the American Academy of Dermatology*, 2026. [doi:10.1016/j.jaad.2026.08.038](https://doi.org/10.1016/j.jaad.2026.08.038)
- Global, regional, and national burden of HIV/AIDS, 1990–2023, with the estimated burden attributable to intimate partner violence and forecasted impacts of funding cuts through 2030: results from the Global Burden of Disease Study 2023. *The Lancet HIV*, 2026. [doi:10.1016/s2352-3018(26)00147-5](https://doi.org/10.1016/s2352-3018(26)00147-5)
- Decoding biological drug names in dermatology: The post-2022 WHO nomenclature revision and its implications for clinical practice. *Journal of the American Academy of Dermatology*, 2026. Senior author. [doi:10.1016/j.jaad.2026.07.093](https://doi.org/10.1016/j.jaad.2026.07.093)
- Co-Occurrence of En Coup de Sabre, Parry-Romberg Syndrome, and Hemimasticatory Spasm: A Case Report. *Case Reports in Dermatology*, 2026. Senior author. [doi:10.1159/000551986](https://doi.org/10.1159/000551986)
- microRNA miR-31-5p confers protection to melanin-deficient vitiligo keratinocytes against UV-B induced DNA damage by activating autophagy machinery. *Scientific Reports*, 2026. [doi:10.1038/s41598-026-53841-5](https://doi.org/10.1038/s41598-026-53841-5)
- Revisiting Leonine Facies: Toward More Inclusive Differential Diagnoses. *Indian Dermatology Online Journal*, 2026. Senior author. [doi:10.4103/idoj.idoj_890_25](https://doi.org/10.4103/idoj.idoj_890_25)

## Contact
- University: aayush.gupta@dpu.edu.in
- Advisory work: aayushggupta@gmail.com
- Qtanea Solutions: hello@qtanea.com